Occuity are delighted to have raised over £2.85 million in our investment round, attracting investment from over 850 investors from 38 countries and becoming the largest MedTech raise on leading crowdfunding platform, Seedrs. 


Register Your Interest

If you are interested in talking to our team about investment opportunities, please complete the form below and a member of our team will contact you accordingly. 

About Occuity

We're revolutionising the way in which some of the world’s most prevalent chronic diseases are detected and managed. Our devices work by harmlessly shining a low power beam of light into the eye, collecting and analysing the return signal and are unlike anything else currently on the market.


We have developed a novel, globally patented (9 granted, 5 pending, 1 in process) non-contacting technology that is able to accurately detect changes in the eye and thereby derive information not only about a patient’s ocular health but also about their broader wellbeing, particularly where this relates to chronic, life-changing conditions.

Occuity is developing its disruptive technology into a range of handheld devices aimed at some of the major health problems of our time. Due to the size of the market, we are particularly interested in addressing diabetes by both developing products that will enable earlier diagnosis of the condition and will also enable non-contacting, pain-free glucose monitoring.

Our first product using the patented technology will be the Occuity PM1 pachymeter, a handheld device for opticians to optically measure the thickness of the cornea to support glaucoma diagnosis. The prototype is at the point of undergoing clinical trials, is due to be ready for sale in the summer of 2021, and is set to entirely disrupt a market worth $275M pa.


Following on from this will be more advanced meters to screen first for diabetes, then for Alzheimer’s Disease and then a personal blood glucose meter for use by people with diabetes. Our products will address markets collectively worth around $35Bn pa.